Health and Healthcare

Amgen : AMGN

All Amgen Articles

701 Articles

Paul Ausick | Apr 21, 2015 at 11:35 AM EDT

Will Amgen Earnings Shape Biotech for the Rest of 2015?

After markets close on Tuesday, Amgen, the second-largest biotech, is scheduled to announce its first-quarter results.

Chris Lange | Apr 13, 2015 at 8:35 AM EDT

Short Sellers Increase Their Bets Against Biotech Stocks

The March 31 short interest data have been compared with the March 13 figures, and for most of the selected…

Jon C. Ogg | Apr 7, 2015 at 3:27 PM EDT

Goldman Sachs Cheapest Stocks, 6 Best Sector By Sector

Jon OggIf there is one firm on Wall Street that investors have been told that they want to pay attention to…

Chris Lange | Apr 6, 2015 at 12:45 PM EDT

Is a Big Share Buyback Coming to DaVita?

DaVita Healthcare Partners has a large amount of cash on its balance sheet and it does not pay a dividend.…

Lee Jackson | Mar 16, 2015 at 8:15 AM EDT

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech…

Chris Lange | Mar 11, 2015 at 9:15 AM EDT

Short Sellers Get More Aggressive on Big Biotech

24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with…

Chris Lange | Feb 26, 2015 at 9:25 AM EST

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech…

Lee Jackson | Feb 18, 2015 at 8:25 AM EST

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid…

Chris Lange | Feb 11, 2015 at 9:40 AM EST

Short Sellers Look Scared of Big Biotech

The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech…

Lee Jackson | Feb 7, 2015 at 9:10 AM EST

Insiders Aggressively Buy Shares as Market Rockets Higher

Logically, it seems that as they stock market zooms higher, insiders who want to buy stock would wait until a…

Jon C. Ogg | Feb 4, 2015 at 10:45 AM EST

Gilead Dividend and Buyback Different From Amgen’s Strategy

Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a…

Chris Lange | Jan 28, 2015 at 11:00 AM EST

Short Sellers Starting to Gang Up on Biotech

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected…

Chris Lange | Jan 13, 2015 at 8:55 AM EST

Short Interest in Biotechs Signals Optimism

24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.

Jon C. Ogg | Dec 17, 2014 at 1:05 PM EST

Is a Biosimilar (Generic) Top Cancer Drug for You?

A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.

Chris Lange | Dec 10, 2014 at 10:00 AM EST

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top…

1 … 26 27 28 29 30 … 47

Amgen : AMGN

All Amgen Articles

Will Amgen Earnings Shape Biotech for the Rest of 2015?

Short Sellers Increase Their Bets Against Biotech Stocks

Goldman Sachs Cheapest Stocks, 6 Best Sector By Sector

Is a Big Share Buyback Coming to DaVita?

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

Short Sellers Get More Aggressive on Big Biotech

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Short Sellers Look Scared of Big Biotech

Insiders Aggressively Buy Shares as Market Rockets Higher

Gilead Dividend and Buyback Different From Amgen’s Strategy

Short Sellers Starting to Gang Up on Biotech

Short Interest in Biotechs Signals Optimism

Is a Biosimilar (Generic) Top Cancer Drug for You?

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Amgen : AMGN

All Amgen Articles

Will Amgen Earnings Shape Biotech for the Rest of 2015?

Short Sellers Increase Their Bets Against Biotech Stocks

Goldman Sachs Cheapest Stocks, 6 Best Sector By Sector

Is a Big Share Buyback Coming to DaVita?

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

Short Sellers Get More Aggressive on Big Biotech

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Short Sellers Look Scared of Big Biotech

Insiders Aggressively Buy Shares as Market Rockets Higher

Gilead Dividend and Buyback Different From Amgen’s Strategy

Short Sellers Starting to Gang Up on Biotech

Short Interest in Biotechs Signals Optimism

Is a Biosimilar (Generic) Top Cancer Drug for You?

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

Featured Reads

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase